Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

VXRT – Vaxart, Inc.

Vaxart, Inc. - Common Stock
VXRT
$0.452
Name : Vaxart, Inc. - Common Stock
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $103,156,800.00
EPSttm : -0.26
finviz dynamic chart for VXRT
Vaxart, Inc. - Common Stock
$0.452
8.59%
$0.0425

Float Short %

9.53

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

0.01

EPS Last/This Y

0.04

EPS This/Next Y

-0.05

Price

0.45

Target Price

4.67

Analyst Recom

1

Performance Q

7.31

Relative Volume

0.63

Beta

1.18

Ticker: VXRT




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02VXRT0.4480.050.0010975
2025-06-03VXRT0.41610.050.8211023
2025-06-04VXRT0.40140.050.0511001
2025-06-05VXRT0.39440.050.1911303
2025-06-06VXRT0.4050.050.2511426
2025-06-09VXRT0.3960.050.1511472
2025-06-10VXRT0.39180.040.0011341
2025-06-11VXRT0.510.040.0611343
2025-06-12VXRT0.52680.040.0114138
2025-06-13VXRT0.68630.040.0214586
2025-06-16VXRT0.6750.040.1516488
2025-06-17VXRT0.59620.040.0416602
2025-06-18VXRT0.61220.040.0116769
2025-06-20VXRT0.580.040.0116619
2025-06-23VXRT0.56580.040.2312804
2025-06-24VXRT0.560.040.0112945
2025-06-25VXRT0.53210.040.0512965
2025-06-26VXRT0.53910.040.1113499
2025-06-27VXRT0.49140.040.3513552
2025-06-30VXRT0.45640.040.0113578
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02VXRT0.45-22.2- -0.29
2025-06-03VXRT0.42-5.6- -0.29
2025-06-04VXRT0.40-5.6- -0.29
2025-06-05VXRT0.40-5.6- -0.29
2025-06-06VXRT0.40-5.6- -0.29
2025-06-09VXRT0.40-5.6- -0.29
2025-06-10VXRT0.39-5.6- -0.29
2025-06-11VXRT0.51-5.6- -0.29
2025-06-12VXRT0.54-5.6- -0.29
2025-06-13VXRT0.69-5.6- -0.29
2025-06-16VXRT0.68-5.6- -0.29
2025-06-17VXRT0.60-5.6- -0.29
2025-06-18VXRT0.61-5.6- -0.29
2025-06-20VXRT0.58-5.6- -0.29
2025-06-23VXRT0.56-5.6- -0.29
2025-06-24VXRT0.56-5.6- -0.29
2025-06-25VXRT0.53-5.6- -0.29
2025-06-26VXRT0.54-5.6- -0.29
2025-06-27VXRT0.49-5.6- -0.29
2025-06-30VXRT0.45-5.6- -0.29
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02VXRT1.67-23.526.46
2025-06-03VXRT1.67-23.526.46
2025-06-04VXRT1.67-23.526.46
2025-06-05VXRT1.67-23.526.46
2025-06-06VXRT1.67-23.526.46
2025-06-09VXRT1.67-23.526.46
2025-06-10VXRT1.67-23.526.46
2025-06-11VXRT1.67-23.526.60
2025-06-12VXRT1.67-23.526.60
2025-06-13VXRT1.67-23.526.60
2025-06-16VXRT1.67-23.526.60
2025-06-18VXRT1.67-23.526.60
2025-06-20VXRT1.67-23.526.60
2025-06-23VXRT1.67-23.526.61
2025-06-24VXRT1.65-23.526.61
2025-06-25VXRT1.65-23.526.61
2025-06-26VXRT1.65-23.529.53
2025-06-27VXRT1.65-23.529.53
2025-06-30VXRT1.65-23.529.53
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

1.65

Institutional Transactions

-23.52

Beta

1.18

Average Sales Estimate Current Quarter

2

Average Sales Estimate Next Quarter

2

Fair Value

Quality Score

23

Growth Score

39

Sentiment Score

4

Actual DrawDown %

98.2

Max Drawdown 5-Year %

-98.7

Target Price

4.67

P/E

Forward P/E

PEG

P/S

2.18

P/B

2.26

P/Free Cash Flow

EPS

-0.27

Average EPS Est. Cur. Y​

-0.29

EPS Next Y. (Est.)

-0.34

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-122.63

Relative Volume

0.63

Return on Equity vs Sector %

-151.3

Return on Equity vs Industry %

-132.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.05

EBIT Estimation

Vaxart, Inc. - Common Stock
Sector: Healthcare
Industry: Biotechnology
Employees: 105
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
stock quote shares VXRT – Vaxart, Inc. Stock Price stock today
news today VXRT – Vaxart, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VXRT – Vaxart, Inc. yahoo finance google finance
stock history VXRT – Vaxart, Inc. invest stock market
stock prices VXRT premarket after hours
ticker VXRT fair value insiders trading